ANDA 71633, held by Chartwell RX. Tolazamide.
As of Nov 21, 2026, ANDA 71633 (Tolazamide), held by Chartwell RX, was first approved by FDA on Dec 9, 1987, with 8 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 9, 1987 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tolazamide100MG · tablet;oral | Tolazamide | Discontinued |
| May 9, 2001 | Supplement 13Manufacturing | Approved | None posted |
| Jan 2, 2001 | Supplement 12Manufacturing | Approved | None posted |
| Apr 3, 1996 | Supplement 11Manufacturing | Approved | None posted |
| Oct 24, 1995 | Supplement 9Manufacturing | Approved | None posted |
| Oct 24, 1995 | Supplement 10Manufacturing | Approved | None posted |
| Jul 24, 1992 | Supplement 7Labeling | Approved | None posted |
| Apr 5, 1990 | Supplement 6Manufacturing | Approved | None posted |
| Nov 8, 1988 | Supplement 1Manufacturing | Approved | None posted |
| Dec 9, 1987 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters